5-alpha reductase inhibitors use in prostatic disease and beyond.

Chislett, Bodie; Chen, David; Perera, Marlon L; Chung, Eric; Bolton, Damien; Qu, Liang G

Chislett, Bodie; Chen, David; Perera, Marlon L; Chung, Eric; Bolton, Damien; Qu, Liang G.

Afiliación

Chislett B; Department of Urology, Austin Health, Heidelberg, Melbourne, VIC, Australia.
Chen D; Young Urology Researchers Organisation (YURO), Melbourne, VIC, Australia.
Perera ML; Department of Urology, Austin Health, Heidelberg, Melbourne, VIC, Australia.
Chung E; Young Urology Researchers Organisation (YURO), Melbourne, VIC, Australia.
Bolton D; Department of Urology, Austin Health, Heidelberg, Melbourne, VIC, Australia.
Qu LG; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Transl Androl Urol ; 12(3): 487-496, 2023 Mar 31.

Article en En | MEDLINE | ID: mdl-37032761

Palabras clave

5-alpha reductase inhibitors (5-ARIs); coronavirus disease (COVID); prostate cancer; review; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transl Androl Urol Año: 2023 Tipo del documento: Article País de afiliación: Australia Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google